Epirubicin
Kirsten Rat Sarcoma (KRAS) pG12C Mutation
AmgenPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Kirsten Rat Sarcoma (KRAS) pG12C Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Amgen | Phase 1 | CC |
Atezolizumab Amgen | Phase 1 | CC |
Docetaxel Amgen | Phase 1 | CC |
Eloxatin Amgen | Phase 1 | CC |
Sotorasib Amgen | Phase 1 | CC |
View all 19 →
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →